@article{6111,
  keywords = {Anti-Infective Agents, Drug Resistance, Multiple, Bacterial, Drug Therapy, Combination, Humans, Leprostatic Agents, leprosy, Levofloxacin, Ofloxacin},
  author = {Gidoh M and Namisato M and Kumano K and Goto M and Nogami R and Ozaki M and Commitee for standards on therapeutic usage of newquinolones },
  title = {[Guideline for the treatment of leprosy by new quinolones].},
  abstract = {<p>Ofloxacin(OFLX) is often applied today as a substitution drug of MDT for drug resistance to dapsone, rifampicin or clofazimine. However, OFLX resistance is also becoming a great concern. Low and/or irregular administration are considered to be the major causes of OFLX resistance. OFLX should be used as a combined therapy, and minimal daily dose of 400 mg of OFLX or 200-300 mg of levofloxacin is required. Quinolone resistance should be considered when no improvement of clinical and/or bacterial index is observed after the treatment for 6 months. In such cases, resistance gene detection is necessary.</p>},
  year = {2004},
  journal = {Nihon Hansenbyo Gakkai zasshi = Japanese journal of leprosy : official organ of the Japanese Leprosy Association},
  volume = {73},
  pages = {65-7},
  month = {2004 Feb},
  issn = {1342-3681},
  language = {jpn},
}